Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Can CRISPR cure sickle-cell disease?

Sickle-cell disease is one of the most common genetic conditions worldwide, with more than 6 million people living with the disease. Three-quarters of them are in sub-Saharan Africa, where childhood mortality due to sickle cell remains high.

Previously, the only curative treatment was a stem-cell transplant, but new trials are investigating the potential of CRISPR–Cas9 gene editing as a tool to cure this chronic condition.

One such trial has already achieved exciting results. For people around the world who are living with sickle cell, these trials could offer hope that long-term cures are just over the horizon.


This article is part of Nature Outlook: Sickle-cell disease, an editorially independent supplement produced with the financial support of third parties. About this content.


Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links